Annetine C. Gelijns
- PROFESSOR & CHAIR Health Evidence and Policy
LL.B., University of Leyden Law School
Civil Law; Economics
LL.M., Universities of Leyden Law School and Utrecht Department of Health Administration, School of Medicine
Medical Human Experiments; Health Economics; Health Systems; Environmental Law; Forensic Psychiatry
Fellowship, Massachusetts Institute of Technology
The Dynamics of Health Service Systems - Systems Dynamic Modeling
Fellowship, John Hopkins University
Computer Assisted Planning for Health Care
Fellowship, University of Utrecht
Scenario Analysis and Health Planning
Ph.D, University of Amsterdam School of Medicine and Department of Science Policy
Innovation in Clinical Practice: The Dynamics of Medical Technology Development.
1994 - 1996
Investigator Award in Health Policy Research
Robert Wood Johnson Foundation, Princeton, NJ
1987 - 1990
The Querido-Award for the most promising young investigator in public health, the National Foundation for Health Promotion and Disease Prevention (Praeventiefonds)
The Hague, the Netherlands
1987 - 1990
International Fellow, Council on Health Care Technology
Institute of Medicine, National Academy of Sciences, Washington, DC
Gelijns A, Gabriel S. Looking beyond Translation — Integrating Clinical Research with Medical Practice. New England Journal of Medicine 2012 May 3; 366(18): 1659-66.
Gardner T, Miller M, O'Gara P, Gelijns A. Building an infrastructure for clinical trials in cardiac surgery. J Thorac Cardiovasc Surg 2011 Aug; 142(2): 265-6.
Gillinov A, Argenziano M, Blackstone E, Iribarne A, DeRose J, Ailawadi G, Russo M, Ascheim D, Parides M, Rodriguez E, Bouchard D, Taddei-Peters W, Geller N, Acker M, Gelijns A. Designing comparative effectiveness trials of surgical ablation for atrial fibrillation: experience of the Cardiothoracic Surgical Trials Network. J Thorac Cardiovasc Surg 2011 Aug; 142(2): 257-64.
Greco G, Egorova N, Gelijns A, Moskowitz A, Manganaro A, Zwolak R, Riles T, Kent K. Development of a novel scoring tool for the identification of large ≥5 cm abdominal aortic aneurysms. Ann Surg 2012 Oct; 252(4): 675-82.
Egorova N, Gelijns A, Moskowitz A, Emond J, Krapf R, Lazar E, Guillerme S, Kaplan H, Greco G. Process of care events in transplantation: effects on the cost of hospitalization. Am J Transplant 2010 Oct; 10(10): 2341-8.
Gelijns A, Ascheim D, Parides M, Kent K, Moskowitz A. Randomized trials in surgery. Surgery 2009 Jun; 145(6): 581-7.
Ascheim D, Gelijns A, Rose E. Innovation with experience using implantable left ventricular assist devices. Circ Heart Fail 2009 Jan; 2(1): 1-2.
Iribarne A, Russo M, Moskowitz A, Ascheim D, Brown L, Gelijns A. Assessing technological change in cardiothoracic surgery. Semin Thorac Cardiovasc Surg 2009 Spring; 21(1): 28-34.
Russo M, Gelijns A, Stevenson L, Sampat B, Aaronson K, Renlund D, Ascheim D, Hong K, Oz M, Moskowitz A, Rose E, Miller L. The Cost of Medical Management in Advanced Heart Failure during the Final Two Years of Life. Rematch Investigators. J Heart Failure 2008 Oct; 14 (8): 651-658.
Egorova N, Moskowitz A, Gelijns A, Weinberg A, Curty J, Rabin-Fastman B, Kaplan H, Cooper M, Fowler D, Emond J, Greco G. Managing the prevention of retained surgical instruments: what is the value of counting? . Annals of Surgery 2008; 247: 13-18.
Neaton J, Normand S, Gelijns A, Starling R, Mann D, Konstam M. Designs for mechanical circulatory support device studies. Journal of Cardiac Failure 2007 Feb; 13(1): 63-74.
Parides M, Moskowitz A, Ascheim D, Rose E, Gelijns A. Progress versus precision: challenges in clinical trial design for left ventricular assist devices. Annals of Thoracic Surgery 2006 Sep; 82(3): 1140-6.
Gelijns A, Thier S. Medical Innovation and Institutional Interdependence; Rethinking University-Industry Connections. . JAMA 2002 January; 287: 72-77.
Rose E, Gelijns A, Moskowitz A. Long Term Use of a Left Ventricular Assist Device for End-Stage Heart Failure. The New England Journal of Medicine 2001; 345: 1435-1443.
Gelijns A, Rosenberg N, Moskowitz A. Capturing the Unexpected Benefits of Medical Research. New Engl J Med 1998; 339: 693-8.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Gelijns during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- MERS International, LLC
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 2nd Floor Room L2-46
1425 Madison Avenue
New York, NY 10029